Astatine-211 Solution Purification With Physiological Reducing Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional methods for producing astatine-211 solutions result in low radiochemical purity, leading to weak accumulation of radioactivity in the thyroid gland during in vivo experiments, limiting their effectiveness in radiotherapy.
Innovation Solution
A production method involving the addition of a physiologically acceptable reducing agent, such as ascorbic acid, sodium ascorbate, cysteine, or glutathione, to a 211At solution to enhance radiochemical purity, followed by pH adjustment to neutral or weakly alkaline conditions, results in a high-purity 211At− solution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional nuclear reaction method is used to produce 211At solution, then production process is simple, but radiochemical purity is low
Solution Approach 1:
A reducing agent (ascorbic acid, sodium ascorbate, cysteine, or glutathione) is introduced as an intermediary substance to convert oxidized astatine species back to astatide ions, thereby improving radiochemical purity without fundamentally changing the nuclear reaction production process
Solution Approach 2:
The oxidation-reduction potential of the solution is changed by adding reducing agents, transforming the chemical state of astatine from oxidized forms to reduced astatide ions, thus improving radiochemical purity while maintaining production simplicity
2Reliability
If low radiochemical purity 211At solution is used, then production process is simple, but accumulation of radioactivity in thyroid gland is weak
Solution Approach 1:
The reducing agent acts as a mediator that ensures astatine is in the correct chemical form (astatide ion) for effective uptake by the sodium iodide symporter in the thyroid gland, thereby improving accumulation effectiveness
Solution Approach 2:
By changing the oxidation state of astatine through reduction, the solution achieves parameters that enhance biological uptake and accumulation in the target organ, improving therapeutic effectiveness
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The high-purity 211At− solution exhibits enhanced accumulation of radioactivity in the thyroid gland, improving the effectiveness of radiotherapy for thyroid gland diseases and other NIS-expressing cancers.
Implementation Method 1
adding a reducing agent to a solution comprising an impurity derived from 211At
Implementation Method 2
helium is accelerated by an accelerator such as a cyclotron, irradiated to a target substance bismuth-209 (209Bi), and 211At is produced in the target substance by the nuclear reaction of 209Bi(α,2n)211At
Implementation Method 3
211At is produced in the target substance by the nuclear reaction of 209Bi(α,2n)211At
Implementation Method 4
the target substance is evaporated by heating to separate 211At
Data Source
AI summary
The invention provides a method for producing a solution containing 211At− (astatide ion) at a high radiochemical purity by using 211At obtained by a nuclear reaction as a starting material, including a step of adding a reducing agent to a solution containing an impurity derived from 211At. The invention also provides a solution containing 211At− (astatide ion) at a radiochemical purity of not less than 30%.